These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12175637)

  • 1. Influence of C4A deficiency on nonresponse to HBsAg vaccination: a new immune response gene.
    Milich DR
    J Hepatol; 2002 Sep; 37(3):396-9. PubMed ID: 12175637
    [No Abstract]   [Full Text] [Related]  

  • 2. C4A deficiency and nonresponse to hepatitis B vaccination.
    Höhler T; Stradmann-Bellinghausen B; Starke R; Sänger R; Victor A; Rittner C; Schneider PM
    J Hepatol; 2002 Sep; 37(3):387-92. PubMed ID: 12175635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HBV neonatal immunization with recombinant vaccine. Part II. Molecular basis of the impaired alloreactivity.
    Martinetti M; Cuccia M; Daielli C; Ambroselli F; Gatti C; Pizzochero C; Belloni C; Orsolini P; Salvaneschi L
    Vaccine; 1995 Apr; 13(6):555-60. PubMed ID: 7483776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatitis B vaccination in patients on chronic hemodialysis].
    Kovacić V; Sain M; Vukman V
    Lijec Vjesn; 2003; 125(5-6):156-8. PubMed ID: 14533468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hepatitis B infections: vaccination and its limitations.
    Leroux-Roels G; Cao T; De Knibber A; Meuleman P; Roobrouck A; Farhoudi A; Vanlandschoot P; Desombere I
    Acta Clin Belg; 2001; 56(4):209-19. PubMed ID: 11603250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccination.
    Paynter HE; Clarke J; McArley A; Williams AJ
    Nephrol Dial Transplant; 1997 Mar; 12(3):623-4. PubMed ID: 9075163
    [No Abstract]   [Full Text] [Related]  

  • 8. Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.
    Wilson JN; Nokes DJ; Medley GF; Shouval D
    Vaccine; 2007 May; 25(18):3705-12. PubMed ID: 17306427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of hepatitis B virus infection in middle school students born after the universal infant vaccination program in Shanghai, China.
    Wang WL; Shu ZJ; Zhou LX; Zhao YR
    Arch Virol; 2012 May; 157(5):901-5. PubMed ID: 22327392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Active hepatitis B vaccination in ulcerative colitis treated with azathioprine].
    Hinrichsen H; Fölsch UR
    Internist (Berl); 1999 Mar; 40(3):327-8. PubMed ID: 10205763
    [No Abstract]   [Full Text] [Related]  

  • 11. [Explanation of hepatitis B virus markers after hepatitis B vaccines inoculation].
    Chen H; Zhu QR
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):240. PubMed ID: 12716528
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B vaccination: time for a booster?
    Shopper T
    LDA J; 1992; 51(3):5-6. PubMed ID: 9518764
    [No Abstract]   [Full Text] [Related]  

  • 13. National Advisory Committee on Immunization (NACI). Revised guidelines for booster vaccination against hepatitis B.
    Can Commun Dis Rep; 1992 Aug; 18(16):121-2. PubMed ID: 1290997
    [No Abstract]   [Full Text] [Related]  

  • 14. Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus.
    Jüptner M; Flachsbart F; Caliebe A; Lieb W; Schreiber S; Zeuner R; Franke A; Schröder JO
    Lupus; 2018 Apr; 27(4):600-609. PubMed ID: 29050534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-dose hepatitis vaccination versus 3-dose regimen.
    Cruess DF
    Pediatrics; 2002 Jun; 109(6):1183; author reply 1183-4. PubMed ID: 12042565
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production.
    Zuckerman JN
    J Med Virol; 1996 Dec; 50(4):283-8. PubMed ID: 8950683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HBs antigenemia and vaccination against hepatitis B virus: attention to chronology of markers].
    Beaulieu S; Lopez Y; Eugène C
    Presse Med; 2000 Oct; 29(32):1762-3. PubMed ID: 11098272
    [No Abstract]   [Full Text] [Related]  

  • 18. [A nested case control study for risk factors impacting hepatitis B vaccination in Hebei, China].
    Ma JC; Han CZ; Qi SX; Tian C; Li J; Zhao SJ; Zhang Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):201-4. PubMed ID: 19031703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
    Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
    Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-dose hepatitis vaccination versus 3-dose regimen.
    Meyerhoff AS; Greenberg DP
    Pediatrics; 2002 Jun; 109(6):1183-4; author reply 1183-4. PubMed ID: 12042564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.